{"name":"Uniquity One (UNI)","slug":"uniquity-one-uni","ticker":"","exchange":"","domain":"uniquityoneuni.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Biological: Solrikitug high dose","genericName":"Biological: Solrikitug high dose","slug":"biological-solrikitug-high-dose","indication":"Treatment of Still's disease","status":"phase_2"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Biological: Solrikitug low dose","genericName":"Biological: Solrikitug low dose","slug":"biological-solrikitug-low-dose","indication":"Treatment of systemic juvenile idiopathic arthritis","status":"phase_2"}]}],"pipeline":[{"name":"Biological: Solrikitug high dose","genericName":"Biological: Solrikitug high dose","slug":"biological-solrikitug-high-dose","phase":"phase_2","mechanism":"Solrikitug is a high-dose biologic that targets the IL-1β pathway.","indications":["Treatment of Still's disease"],"catalyst":""},{"name":"Biological: Solrikitug low dose","genericName":"Biological: Solrikitug low dose","slug":"biological-solrikitug-low-dose","phase":"phase_2","mechanism":"Solrikitug is a low-dose biological drug that targets the IL-1β pathway.","indications":["Treatment of systemic juvenile idiopathic arthritis"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":2},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}